CollPlant Biotechnologies (NASDAQ:CLGN) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research report report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $14.00 price target on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Wednesday, August 21st. EF Hutton Acquisition Co. I upgraded shares of CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th.

CollPlant Biotechnologies Stock Performance

Shares of NASDAQ:CLGN opened at $4.48 on Wednesday. CollPlant Biotechnologies has a 52-week low of $3.31 and a 52-week high of $6.99. The business’s 50 day simple moving average is $4.29 and its two-hundred day simple moving average is $4.83. The firm has a market cap of $51.30 million, a P/E ratio of -2.91 and a beta of 0.44.

Hedge Funds Weigh In On CollPlant Biotechnologies

A number of large investors have recently bought and sold shares of the stock. Villere ST Denis J & Co. LLC boosted its stake in shares of CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares during the period. Benjamin Edwards Inc. bought a new stake in CollPlant Biotechnologies during the 3rd quarter valued at $112,000. Finally, Pinnacle Associates Ltd. boosted its position in CollPlant Biotechnologies by 6.4% during the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock valued at $2,805,000 after buying an additional 33,905 shares during the period. 21.69% of the stock is owned by hedge funds and other institutional investors.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.